Abbott Laboratories (ABT) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ABT Revenue Growth
Revenue Breakdown (FY 2024)
ABT's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
ABT Revenue Analysis (2013–2024)
As of May 6, 2026, Abbott Laboratories (ABT) generated trailing twelve-month (TTM) revenue of $43.84 billion, reflecting solid growth of +6.9% year-over-year. The most recent quarter (Q3 2025) recorded $11.37 billion in revenue, up 2.0% sequentially.
Looking at the longer-term picture, ABT's 5-year compound annual growth rate (CAGR) stands at +5.6%, indicating steady revenue expansion. The company achieved its highest annual revenue of $43.65 billion in 2022.
Revenue diversification analysis shows ABT's business is primarily driven by Medical Devices (45%), Diagnostic Products (22%), and Nutritional Products (20%).
When compared to Healthcare sector peers including MDT (+6.9% YoY), BSX (+19.9% YoY), and BDX (+6.2% YoY), ABT has underperformed the peer group in terms of revenue growth. Compare ABT vs MDT →
ABT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ABTCurrent | $43.8B | +6.9% | +5.6% | 16.3% | |
 MDT | $33.5B | +6.9% | +3.0% | 17.8% | |
 BSX | $20.1B | +19.9% | +15.2% | 19.8% | |
 BDX | $21.8B | +6.2% | +6.3% | 11.8% | |
 BAX | $11.2B | +5.1% | -0.7% | -2.7% | |
 EW | $6.1B | +11.2% | +6.7% | 27.0% |
ABT Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $41.95B | +4.6% | $21.32B | 50.8% | $6.83B | 16.3% |
| 2023 | $40.11B | -8.1% | $20.04B | 50.0% | $6.43B | 16.0% |
| 2022 | $43.65B | +1.3% | $22.32B | 51.1% | $8.36B | 19.2% |
| 2021 | $43.08B | +24.5% | $23.21B | 53.9% | $9.20B | 21.4% |
| 2020 | $34.61B | +8.5% | $17.38B | 50.2% | $5.29B | 15.3% |
| 2019 | $31.90B | +4.3% | $16.69B | 52.3% | $4.59B | 14.4% |
| 2018 | $30.58B | +11.6% | $15.82B | 51.7% | $3.84B | 12.6% |
| 2017 | $27.39B | +31.3% | $13.07B | 47.7% | $1.97B | 7.2% |
| 2016 | $20.85B | +2.2% | $11.24B | 53.9% | $3.25B | 15.6% |
| 2015 | $20.41B | +0.8% | $10.96B | 53.7% | $2.95B | 14.5% |
Full ABT Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Should I Buy ABT Right Now?
Bull case, key risks, Wall St analyst verdict, and what council investors are saying — updated daily.
See ABT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ABT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ABT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonABT — Frequently Asked Questions
Quick answers to the most common questions about buying ABT stock.
Is ABT's revenue growth accelerating or slowing?
ABT maintains +6.9% revenue growth, in line with its 5-year CAGR of +5.6%. TTM revenue stands at $43.8B. Growth rate remains consistent with historical average.
What is ABT's long-term revenue growth rate?
Abbott Laboratories's 5-year revenue CAGR of +5.6% reflects the sustained expansion pattern. Current YoY growth of +6.9% is near this long-term average.
How is ABT's revenue distributed by segment?
ABT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.